31st May 2006 12:15
Hikma Pharmaceuticals Plc31 May 2006 Notification of Transaction by a Director LONDON, 31 May 2006 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)(DIFX:HIK) announces that Mr. Samih Darwazah, Chairman and Chief Executive ofthe Company, has today notified the Company of the transfer of his entire directholding of 1,074,506 ordinary shares of 10 pence each in the capital of theCompany, to HMS Holding SAL, a company 99.66 percent owned by him. The remainingoutstanding shares of HMS Holding SAL are held equally between Mr. Darwazah'swife, and his son, Mazen Darwazah. The transfer was made for nil considerationand was made on 31 May 2006. The shares transferred represent 0.642 per cent. of the issued ordinary sharesof 10 pence each in the capital of the Company, and following the notificationMr. Darwazah no longer has a direct holding in the Company's ordinary shares.HMS Holding SAL has agreed to continue the same lock-up arrangements as Mr.Darwazah in respect of the shares transferred. The holding of Darhold Limited, acompany in which Mr. Darwazah is a shareholder, remains unchanged. Mr. Darwazah is both a director and a Person Discharging ManagerialResponsibility in respect of the Company, and the above notification relatesboth to DR 3.1.4R(1)(a) and section 324 (as extended by section 328) of theCompanies Act 1985. -- ENDS -- Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760Company SecretarySusan Ringdal +44 20 7399 2760Investor Relations Director Brunswick Group Jon Coles / Wendel Verbeek / Justine McIlroy / Alex Tweed +44 20 7404 5959 About HikmaHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals